Medical device company nContact, a developer of products to treat arrhythmias, has raised close to half a million dollars.
The Morrisville, North Carolina company secured a total of $433,761 in debt financing from one investor, according to securities filings. That’s a small amount compared to the company’s venture capital haul to date; nContact has raised more than $42 million in financing, including a 2010 $16 million series D round from venture capital firms Intersouth Partners, Harbert Venture Partners, Finistere Ventures, Massey Burch Capital and ZMV Associates.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Founded in 2005, nContact focuses on developing catheters and surgical ablation devices for arrhythmia treatment, including atrial fibrillation. The company has developed a way to perform minimally invasive ablation procedures to treat arrhythmias. The devices can work on a beating heart without chest incisions or ports. NContact’s device treats patients with enlarged atria, a group representing the majority of atrial fibrillation patients.
